Comparison of Curcumin Bioavailability

NCT03530436 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-01-10

No results posted yet for this study

Summary

The curcuminoids curcumin, demethoxycurcumin and bisdemethoxycurcumin can be found in the rhizome of turmeric (Curcuma longa). Curcumin is widespread used for colouring foods. Based on its natural low bioavailability and the number of its effects on human health, several approaches such as increasing its water solubility or inhibiting its metabolism were taken to improve its bioavailability. Pharmacokinetics of curcumin from various supplements using those different mechanisms have been compared to the one of native curcumin. The investigator's study here will compare the bioavailability of curcumin from eight different curcumin formulations with native curcumin and between themselves. The study will folllow a single dose (in form of curcumin formulations, normalized to 207 mg curcumin), placebo-controlled, randomized, double-blind, nine-armed crossover study design with ≥ 1-week washout periods. Plasma samples will be collected at intervals up to 24 hours after intake. Investigators will compare the pharmacokinetics between the different curcumin formulations and to native curcumin.

Conditions

  • Safety After Oral Intake
  • Pharmacokinetics After Oral Intake

Interventions

DIETARY_SUPPLEMENT

Native turmeric extract

207 mg curcumin

DIETARY_SUPPLEMENT

Native turmeric extract with 7-9% volatile turmeric oils

207 mg curcumin

DIETARY_SUPPLEMENT

Turmeric extract plus mixture of phytochemicals

207 mg curcumin

DIETARY_SUPPLEMENT

Cyclodextrin complex of curcuminoids

207 mg curcumin

DIETARY_SUPPLEMENT

Turmeric oleoresin

207 mg curcumin

DIETARY_SUPPLEMENT

Liposomal curcumin

207 mg curcumin

DIETARY_SUPPLEMENT

Phytosomal curcumin

207 mg curcumin

DIETARY_SUPPLEMENT

Micellar turmeric extract

207 mg curcumin

Sponsors & Collaborators

  • University of Hohenheim

    lead OTHER

Principal Investigators

  • Jan Frank, Prof. Dr. · University of Hohenheim

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-07
Primary Completion
2018-08-10
Completion
2018-11-07

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03530436 on ClinicalTrials.gov